173 related articles for article (PubMed ID: 27995724)
1. Canagliflozin versus placebo for post-bariatric surgery patients with persistent type II diabetes: A randomized controlled trial (CARAT).
Kheniser K; Kashyap SR
Diabetes Obes Metab; 2017 Apr; 19(4):609-610. PubMed ID: 27995724
[No Abstract] [Full Text] [Related]
2. Efficacy and safety of titrated canagliflozin in patients with type 2 diabetes mellitus inadequately controlled on metformin and sitagliptin.
Rodbard HW; Seufert J; Aggarwal N; Cao A; Fung A; Pfeifer M; Alba M
Diabetes Obes Metab; 2016 Aug; 18(8):812-9. PubMed ID: 27160639
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial.
Lavalle-González FJ; Januszewicz A; Davidson J; Tong C; Qiu R; Canovatchel W; Meininger G
Diabetologia; 2013 Dec; 56(12):2582-92. PubMed ID: 24026211
[TBL] [Abstract][Full Text] [Related]
4. An investigation into the durability of glycemic control in patients with type II diabetes initiated on canagliflozin or sitagliptin: A real-world analysis of electronic medical records.
Wysham CH; Lefebvre P; Pilon D; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Duh MS; Ingham M
J Diabetes Complications; 2019 Feb; 33(2):140-147. PubMed ID: 30554838
[TBL] [Abstract][Full Text] [Related]
5. Canagliflozin in Conjunction With Sulfonylurea Maintains Glycemic Control and Weight Loss Over 52 Weeks: A Randomized, Controlled Trial in Patients With Type 2 Diabetes Mellitus.
Yale JF; Xie J; Sherman SE; Garceau C
Clin Ther; 2017 Nov; 39(11):2230-2242.e2. PubMed ID: 29103664
[TBL] [Abstract][Full Text] [Related]
6. Role of Canagliflozin on function of CD34+ve endothelial progenitor cells (EPC) in patients with type 2 diabetes.
Nandula SR; Kundu N; Awal HB; Brichacek B; Fakhri M; Aimalla N; Elzarki A; Amdur RL; Sen S
Cardiovasc Diabetol; 2021 Feb; 20(1):44. PubMed ID: 33581737
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of canagliflozin by baseline HbA1c and known duration of type 2 diabetes mellitus.
Wilding JP; Blonde L; Leiter LA; Cerdas S; Tong C; Yee J; Meininger G
J Diabetes Complications; 2015 Apr; 29(3):438-44. PubMed ID: 25660137
[TBL] [Abstract][Full Text] [Related]
8. Effects of canagliflozin compared with placebo on major adverse cardiovascular and kidney events in patient groups with different baseline levels of HbA
Young TK; Li JW; Kang A; Heerspink HJL; Hockham C; Arnott C; Neuen BL; Zoungas S; Mahaffey KW; Perkovic V; de Zeeuw D; Fulcher G; Neal B; Jardine M
Diabetologia; 2021 Nov; 64(11):2402-2414. PubMed ID: 34448033
[TBL] [Abstract][Full Text] [Related]
9. Effectiveness, treatment durability, and treatment costs of canagliflozin and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes in the USA.
Singhal M; Tan H; Coleman CI; Han M; Nguyen C; Ingham M
BMJ Open Diabetes Res Care; 2019; 7(1):e000704. PubMed ID: 31798890
[TBL] [Abstract][Full Text] [Related]
10. Glycaemic efficacy of canagliflozin is largely independent of baseline β-cell function or insulin sensitivity.
Matthews DR; Zinman B; Tong C; Meininger G; Polidori D
Diabet Med; 2016 Dec; 33(12):1744-1747. PubMed ID: 26600115
[No Abstract] [Full Text] [Related]
11. Effect of the sodium glucose co-transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus.
Sha S; Polidori D; Heise T; Natarajan J; Farrell K; Wang SS; Sica D; Rothenberg P; Plum-Mörschel L
Diabetes Obes Metab; 2014 Nov; 16(11):1087-95. PubMed ID: 24939043
[TBL] [Abstract][Full Text] [Related]
12. POSTOPERATIVE INSULIN REQUIREMENTS IN BARIATRIC SURGERY.
Diemer DM; Terry KL; Matthews M; Romich E; Saran H; Lansang MC
Endocr Pract; 2017 Dec; 23(12):1369-1374. PubMed ID: 29019715
[TBL] [Abstract][Full Text] [Related]
13. Effect of canagliflozin on left ventricular diastolic function in patients with type 2 diabetes.
Matsutani D; Sakamoto M; Kayama Y; Takeda N; Horiuchi R; Utsunomiya K
Cardiovasc Diabetol; 2018 May; 17(1):73. PubMed ID: 29788955
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy and safety of canagliflozin in combination with insulin in Japanese patients with type 2 diabetes mellitus.
Inagaki N; Harashima SI; Kaku K; Kondo K; Maruyama N; Otsuka M; Kawaguchi Y; Iijima H
Diabetes Obes Metab; 2018 Apr; 20(4):812-820. PubMed ID: 29110384
[TBL] [Abstract][Full Text] [Related]
15. Effects of once-weekly semaglutide vs once-daily canagliflozin on body composition in type 2 diabetes: a substudy of the SUSTAIN 8 randomised controlled clinical trial.
McCrimmon RJ; Catarig AM; Frias JP; Lausvig NL; le Roux CW; Thielke D; Lingvay I
Diabetologia; 2020 Mar; 63(3):473-485. PubMed ID: 31897524
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of canagliflozin in combination with insulin: a double-blind, randomized, placebo-controlled study in Japanese patients with type 2 diabetes mellitus.
Inagaki N; Harashima S; Maruyama N; Kawaguchi Y; Goda M; Iijima H
Cardiovasc Diabetol; 2016 Jun; 15():89. PubMed ID: 27316668
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease.
Yale JF; Bakris G; Cariou B; Yue D; David-Neto E; Xi L; Figueroa K; Wajs E; Usiskin K; Meininger G
Diabetes Obes Metab; 2013 May; 15(5):463-73. PubMed ID: 23464594
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial.
Kadowaki T; Inagaki N; Kondo K; Nishimura K; Kaneko G; Maruyama N; Nakanishi N; Iijima H; Watanabe Y; Gouda M
Diabetes Obes Metab; 2017 Jun; 19(6):874-882. PubMed ID: 28177187
[TBL] [Abstract][Full Text] [Related]
19. Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.
Chow W; Miyasato G; Kokkotos FK; Bailey RA; Buysman EK; Henk HJ
Clin Ther; 2016 Sep; 38(9):2071-82. PubMed ID: 27596020
[TBL] [Abstract][Full Text] [Related]
20. Characteristics and outcomes of patients with type 2 diabetes mellitus treated with canagliflozin: a real-world analysis.
Buysman EK; Chow W; Henk HJ; Rupnow MF
BMC Endocr Disord; 2015 Nov; 15():67. PubMed ID: 26527413
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
